The safety profile of Soliris (eculizumab) in real-world practice is similar to that reported in clinical trials, according to…
Articles by Marisa Wexler, MS
Most patients and caregivers living with atypical hemolytic uremic syndrome (aHUS) prefer Ultomiris (ravulizumab-cwvz) over Soliris (eculizumab),…
A case study of atypical hemolytic uremic syndrome (aHUS) caused by a new mutation in the DGKE gene highlights…
A young adult with atypical hemolytic uremic syndrome (aHUS) in India successfully received a transplanted kidney from a donor…
A boy with atypical hemolytic uremic syndrome (aHUS) experienced a disease relapse followed by unusual symptoms, including bone tissue…
People with atypical hemolytic uremic syndrome (aHUS) who start treatment with Soliris (eculizumab) or Ultomiris (ravulizumab) —…
For the first time in South Korea, a patient who developed atypical hemolytic uremic syndrome (aHUS) after undergoing a…
About half of the atypical hemolytic uremic syndrome (aHUS) patients had clinically relevant anxiety and more than a quarter…
Soliris (eculizumab) was effective in managing atypical hemolytic uremic syndrome (aHUS), which arose in a man as a…
A substantial number of people with atypical hemolytic uremic syndrome (aHUS) carry rare structural variations in a part of…